
Opinion|Videos|July 17, 2024
Treatment-free survival in IO/TKI
Author(s)Matthew T. Campbell, MD, MS, Rana R. McKay, MD
Medical experts specializing in clear cell renal cell carcinoma examine the concept of treatment-free survival in immunotherapy/tyrosine kinase inhibitor (IO/TKI) regimens, addressing both the advantages and potential drawbacks.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Multimodal AI Outperforms Oncotype DX in Predicting Late Breast Cancer Recurrence
2
T-DXd Benefit Consistent Across Subgroups in High-Risk HER2+ Breast Cancer
3
Sacituzumab Govitecan Improves QOL in Untreated Advanced TNBC
4
FDA Grants Priority Review to Nivolumab-AVD in Classical Hodgkin Lymphoma
5








































